Zsa Zsa Weerts

General introduction 23 1 Rome IV Diagnostic Questionnaire for Adults. Gastroenterology 2016;150:1481-1491. 24. Lovell R, Ford A. Global prevalence of and risk factors for irritable bowel syndrome: a meta- analysis. Clin Gastroenterol Hepatol 2012;10: 712-721 e714. 25. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014;40: 1023-1034. 26. Cash B. Economic impact of irritable bowel syndrome: what does the future hold? Am J Manag Care 2005;11:S4-6. 27. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122-3129. 28. Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007;26:237-248. 29. Silk D. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol 2001;13:1327- 1332. 30. Corsetti M, Whorwell P. The global impact of IBS: time to think about IBS-specific models of care? Therap Adv Gastroenterol 2017;10:727- 736. 31. Flik CE, Laan W, Smout AJ, et al. Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands. BMC Gastroenterol 2015;15:168. 32. Ballou S, Keefer L. The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterol Motil 2017:29(4). 33. Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep 2009;11: 265-269. 34. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health- related quality of life, Gastroenterology. 2000;119:654-660. 35. Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009;104:1984- 1991. 36. Ludidi S, Conchillo JM, Keszthelyi D, et al. Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil 2012;24:729-733, e345-726. 37. Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain 2009;141:191- 209. 38. Boeckxstaens GE, Wouters MM. Neuroimmune factors in functional gastrointestinal disorders: A focus on irritable bowel syndrome. Neurogastroenterol Motil 2017;29. 39. Ruggiero DA, Underwood MD, Mann JJ, et al. The human nucleus of the solitary tract: visceral pathways revealed with an "in vitro" postmortem tracing method. J Auton Nerv Syst 2000;79:181-190. 40. Yakunina N, Kim SS, Nam EC. Optimization of Transcutaneous Vagus Nerve Stimulation Using Functional MRI. Neuromodulation 2017;20:290-300. 41. Saper CB. The central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Annu Rev Neurosci 2002;25:433-469. 42. Pellissier S, Dantzer C, Mondillon L, et al. Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome. PLoS One 2014; 9(9):e105328. 43. Spaziani R, Bayati A, Redmond K, et al. Vagal dysfunction in irritable bowel syndrome assessed by rectal distension and baroreceptor sensitivity. Neurogastroenterol Motil 2008;20:336-342. 44. Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut- Brain Axis. Front Neurosci 2018;12:49. 45. Blackshaw LA. Transient receptor potential cation channels in visceral sensory pathways. Br J Pharmacol 2014;171:2528-2536. 46. Stagg AJ, Hornsby E, Wing ES, et al. P016 Constitutive activity of the cation channel TRPM8 regulates monocyte to macrophage transition in humans to control intestinal inflammation. J Crohns Colitis 2019;13:S094- S094. 47. de Jong PR, Takahashi N, Peiris M, et al. TRPM8 on mucosal sensory nerves regulates colitogenic responses by innate immune cells via CGRP. Mucosal Immunol 2015;8:491-504.